Annovis Bio, Inc. Insider Trading

ANVS

⊜ Compare

Last 12 months

Insiders bought $2.26M on the open market and sold nothing.

Net open-market

+$2.26M

7 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

1 / 0

executives and directors

Last open-market buy

May 2026

May 20, 2026

Get an email when ANVS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 20	Michael B Hoffman Director	Bought 3 parts	76,344	$1.87 average	143K	2.2%	Form 4
Apr 2	Michael B Hoffman Director	Bought	713,800	$2.10	$1.5M	26%	Form 4
Dec 8, 2025	Michael B Hoffman Director	Bought 2 parts	45,000	$4.31 average	194K	1.6%	Form 4
Nov 24, 2025	Michael B Hoffman Director	Bought 4 parts	39,200	$4.08 average	160K	1.4%	Form 4
Nov 24, 2025	Michael B Hoffman Director	Bought 4 parts	39,200	$4.08 average	160K	1.4%	Form 4
Nov 21, 2025	Michael B Hoffman Director	Bought 2 parts	20,000	$3.50 average	70K	0.7%	Form 4
Nov 14, 2025	Michael B Hoffman Director	Bought	15,000	$2.11	32K	0.6%	Form 4
Oct 28, 2025	Maria-Luisa Maccecchini President & CEO	Bought	97,561	$2.05	200K	8.8%	Form 4
Oct 28, 2025	Michael B Hoffman Director	Bought	975,610	$2.05	$2M	57%	Form 4

May 20
Michael B Hoffman
Director · bought 76,344 at avg $1.87
143K
2.2% of stake
Apr 2
Michael B Hoffman
Director · bought 713,800 at $2.10
$1.5M
26% of stake
Dec 8, 2025
Michael B Hoffman
Director · bought 45,000 at avg $4.31
194K
1.6% of stake
Nov 24, 2025
Michael B Hoffman
Director · bought 39,200 at avg $4.08
160K
1.4% of stake
Nov 24, 2025
Michael B Hoffman
Director · bought 39,200 at avg $4.08
160K
1.4% of stake
Nov 21, 2025
Michael B Hoffman
Director · bought 20,000 at avg $3.50
70K
0.7% of stake
Nov 14, 2025
Michael B Hoffman
Director · bought 15,000 at $2.11
32K
0.6% of stake
Oct 28, 2025
Maria-Luisa Maccecchini
President & CEO · bought 97,561 at $2.05
200K
8.8% of stake
Oct 28, 2025
Michael B Hoffman
Director · bought 975,610 at $2.05
$2M
57% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ANVS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANVS

CompareIntrinsic value

ONCOOnconetix Inc.

$0.66+15.69%50

MRKRMarker Therapeutics, Inc.

$1.01+3.06%25

VTVTvTv Therapeutics Inc.

$24.03+2.04%40

LIXTLixte Biotechnology Holdings Inc.

$3.60+2.27%10

ETONEton Pharmaceuticals Inc.

$50.72-0.45%75

CATXPerspective Therapeutics Inc.

$0.87-1.11%10

ARDXArdelyx Inc.

$3.27+7.92%40

TENXTenax Therapeutics Inc.

$1.81-1.63%10

Spot a number that looks wrong? Check it in ANVS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ANVS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.